Research Peptides for Metabolic Health
A neutral, evidence-led index of the major metabolic research peptides studied in UK and international laboratories. Filter by category, UK regulatory status, or search by name or mechanism.
Showing 21 of 21 peptides
GLP-1 / GIP Receptor Agonists
Incretin-mimetic peptides researched for body weight, glycaemic control and metabolic remodelling.
Tirzepatide
also known as LY3298176, Mounjaro
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly, demonstrating unprecedented mean body-weight reductions of approximately 22% in the landmark SURMOUNT-1 trial at 72 weeks.
Retatrutide
also known as LY3437943, triple agonist GLP-1/GIP/glucagon
A once-weekly triple GLP-1, GIP, and glucagon receptor agonist developed by Eli Lilly, demonstrating mean body-weight reductions of approximately 24% at 48 weeks in Phase 2 research.
Semaglutide
also known as Ozempic, Wegovy
A long-acting GLP-1 receptor monoagonist developed by Novo Nordisk, widely researched in STEP and SUSTAIN trials and MHRA-licensed in the UK for type 2 diabetes and chronic weight management.
Liraglutide
also known as Victoza, Saxenda
A first-generation once-daily GLP-1 receptor agonist developed by Novo Nordisk, MHRA-licensed as Victoza for type 2 diabetes and Saxenda for weight management, foundational to the incretin agonist research field.
Growth Hormone Secretagogues
Peptides that stimulate endogenous growth hormone release, studied for lean mass, recovery and lipolysis.
Tesamorelin
also known as Egrifta, TH9507
A synthetic analogue of growth hormone-releasing hormone (GHRH) developed by Theratechnologies, established in clinical research for visceral adiposity reduction in HIV-associated lipodystrophy, now investigated as a broader metabolic research compound.
CJC-1295 / Ipamorelin
also known as CJC-1295, DAC:GRF
A research combination of CJC-1295 (a long-acting GHRH analogue developed by ConjuChem) and Ipamorelin (a selective ghrelin-mimetic GH secretagogue developed by Helsinn/Novo Nordisk), studied together for synergistic pulsatile growth hormone stimulation.
Lipolytic Peptide Fragments
Truncated growth-hormone fragments retaining fat-mobilising activity without growth-promoting effects.
AOD-9604
also known as Anti-Obesity Drug 9604, hGH Frag 177-191 (Tyr-hGH 177-191)
A modified C-terminal fragment of human growth hormone (residues 176–191 with an additional N-terminal tyrosine) developed by Metabolic Pharmaceuticals for targeted lipolysis research, without the growth-promoting IGF-1 axis effects of intact hGH.
HGH Fragment 176-191
also known as HGH Frag 176-191, Growth Hormone Fragment 176-191
The C-terminal 16-amino acid fragment of human growth hormone (residues 176–191), researched as a selective lipolytic agent in preclinical models without the IGF-1 stimulating or growth-promoting properties of intact hGH.
How to read a molecule profile
Every profile on this hub separates UK-licensed prescription medicines (tirzepatide, semaglutide, liraglutide, dulaglutide, exenatide) from investigational compounds (retatrutide, cagrilintide, CagriSema, survodutide, mazdutide, pemvidutide, cotadutide, orforglipron, danuglipron, MariTide) and from research-only compounds (AOD-9604, HGH fragment 176-191, CJC-1295/ipamorelin). The regulatory-status badge on each card tells you which category the molecule sits in today; the badge on the underlying profile page carries the same status text plus the SmPC framing.
The category matters because it constrains what a profile can and cannot say. For a UK-licensed medicine, the SmPC governs the language on indication, dose, contraindication and warning; the profile summarises this and links to trial and regulatory sources. For an investigational compound, no MHRA-licensed indication exists — the profile summarises the published trial evidence and is explicit that use outside an authorised research setting is not sanctioned. For a research-only compound, no human therapeutic indication exists in the UK — the profile is a scientific-literature summary and states plainly that human use is not the intended scope.
Every profile is structured the same way: overview, discovery history, mechanism of action, researched effects, theoretical research protocols (trial-record only), administration routes, stability, safety profile, regulatory status, key research studies, FAQs, and related peptides. The site does not provide dosing recommendations, does not rank or link to suppliers, and does not make prescribing recommendations. Where a medicine is UK-licensed, any actual use is via a qualified UK prescriber following appropriate clinical assessment.